The aim of the study are to compare trends in diagnosis and treatment of adenocarcinoma of the cervix (AC) to squamous cell carcinoma of the cervix (SCC) and to examine associations between stage at diagnosis and guideline-concordant treatment with race, age, and insurance type for AC and SCC.
Materials and Methods
We performed a retrospective cohort study of cervical AC (n = 18,811) and SCC (n = 68,421) from the 2004–2017 National Cancer Database. We used generalized linear models to evaluate trends in frequency of histologies and to evaluate associations between race, age, and insurance status with stage of diagnosis and receipt of National Comprehensive Cancer Network guideline–concordant treatment for AC and SCC.
The proportion of AC relative to SCC increased from 19.4% (95% CI = 18.4–20.5) to 23.2% (95% CI = 22.2–24.2) from 2004 to 2017 (p < .001). Compared with SCC, women with AC were younger, more likely to be White, and privately insured (p < .001). Older women with AC were 44% less likely to be diagnosed with early-stage disease than younger women (adjusted relative risk = 0.56, 95% CI = 0.52–0.60); there was no significant difference for SCC. Black women with AC were 16% less likely to be diagnosed with early-stage disease (adjusted relative risk [aRR] = 0.84, 95% CI = 0.79–0.89) than White women. Women with public insurance were less likely to be diagnosed at an early stage for both AC (aRR = 0.81, 95% CI = 0.78–0.84) and SCC (aRR = 0.79, 95% CI = 0.77–0.81). Rates of guideline-concordant treatment were similar for AC and SCC, with minimal differences by age, race, and insurance.
As the proportion of AC to SCC rises, important race and age-related disparities must be addressed to reduce unnecessary morbidity and death.